Advances in Difficult to Treat Cancers, Novel Uses of Targeted Therapies for Metastatic Cancers, and New Findings on Disparities in Care to be Presented at Largest Global Clinical Cancer Research Meeting

For immediate release
May 3, 2022


Rachel Cagan Facci

ALEXANDRIA, Va. – Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Advances in therapies for rare and pediatric cancers, findings on disparities among patients with cancer, and new treatment options for patients with advanced breast, colorectal, and pancreatic cancers are among the topics that will be highlighted in the meeting’s official Press Program.  

The 2022 ASCO Annual Meeting will take place June 3-7 in Chicago and online. The theme of this year’s conference is Advancing Equitable Cancer Care Through Innovation. 

More than 2,800 abstracts were accepted for presentation at the Annual Meeting, and more than 2,400 additional abstracts were accepted for online publication. The majority of these abstracts will be publicly released on on Thursday, May 26, at 5:00 PM (ET). Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released at 7:00 AM (CT)/8:00 AM (ET) on their day of scientific presentation at the meeting. The complete embargo schedule is available online


To coincide with the release of abstracts on May 26, an embargoed, virtual press briefing for media will be held earlier that day to highlight four significant abstracts on the theme of equity in cancer care from this group. The embargo will lift on May 26 at 5:00 PM (ET) for the following studies:

  • A study examining the association between Medicaid and other social services spending on racial and ethnic disparities and overall survival for newly diagnosed patients with cancer. (Abstract 6509) 
  • A retrospective study examining racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma. (Abstract 10005) 
  • A survey looking at participation in clinical trials among Black patients with metastatic breast cancer. (Abstract 1014
  • A retrospective study of disparities in the use of telemedicine during the COVID-19 pandemic. (Abstract 6511


During the Annual Meeting, a “News of the Day” press briefing will be held on Friday, June 3 from 12:30-1:15 PM (CT) and Saturday, Sunday, and Monday (June 4-6) from 8:00-9:00 AM (CT). LBAs that will be featured in these daily, on-site press briefings are listed below. A press briefing schedule detailing which abstracts will be highlighted each day is also available online.

  • A phase III prospective trial comparing panitumumab and bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type metastatic colorectal cancer. (Abstract LBA1) 
  • A phase III trial assessing different chemotherapy regimens in patients with recurrent and primary refractory Ewing sarcoma, the first randomized trial in this patient group. (Abstract LBA2) 
  • A randomized phase III study comparing trastuzumab deruxtecan with a treatment of a physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer. (Abstract LBA3) 
  • A phase III study of lenalidomide, bortezomib, and dexamethasone with or without autologous stem cell transplantation and lenalidomide maintenance to progression for newly diagnosed multiple myeloma. (Abstract LBA4) 
  • A randomized phase II trial examining the use of adjuvant chemotherapy guided by liquid biopsy in stage II colon cancer. (Abstract LBA100) 
  • A prospective trial analyzing the omittance of radiotherapy following breast conserving surgery in patients with a certain type of breast cancer. (Abstract LBA501) 
  • A randomized phase III trial comparing sacituzumab govitecan with a treatment of a physician’s choice in patients with hormone receptor-positive/HER2-negative advanced breast cancer. (Abstract LBA1001) 
  • A phase II trial analyzing dabrafenib plus trametinib in pediatric patients with low-grade glioma with BRAF-V600 mutations. (LBA 2002) 
  • A randomized trial assessing the clinical efficacy and safety of nimotuzumab combined with gemcitabine in KRAS wild-type locally advanced or metastatic pancreatic cancer. (Abstract LBA4011)  
  • First international phase III trial of ibrutinib plus bendamustine-rituximab in patients with mantle cell lymphoma, a rare type of non-Hodgkin lymphoma. (Abstract LBA7502


Media registration: To participate in the Annual Meeting press briefings and/or register to attend the Meeting in person in Chicago, please visit ASCO’s Media Headquarters at Step-by-step instructions are available online

Media Headquarters submission must be completed no later than Wednesday, May 18, to participate in the pre-meeting press briefing on May 26. Pre-registration is also required for on-site attendance and must be completed by this date. 

Annual Meeting Media Resource Center: Visit for press releases, the press briefing schedule, embargo policies, high-resolution photos, and the Virtual Press Room (an online repository of corporate and institutional press materials from third-party organizations). 

Cancer.Net: ASCO’s website for oncologist-approved cancer information 


About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer,  the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.